Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs). METHODS: Eligible patients received daily temozolomide (50 mg/m(2)) continuously until progression. The primary endpoint was progression-free...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Omuro, Antonio, Chan, Timothy A., Abrey, Lauren E., Khasraw, Mustafa, Reiner, Anne S., Kaley, Thomas J., DeAngelis, Lisa M., Lassman, Andrew B., Nolan, Craig P., Gavrilovic, Igor T., Hormigo, Adilia, Salvant, Cynthia, Heguy, Adriana, Kaufman, Andrew, Huse, Jason T., Panageas, Katherine S., Hottinger, Andreas F., Mellinghoff, Ingo
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2013
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548585/
https://ncbi.nlm.nih.gov/pubmed/23243055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos295
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы